William Arsani's Form 4/A amendment
AmendedDesign Therapeutics, Inc. (DSGN) · filed Sep 6, 2023
- Accession no.
- 0001209191-23-048441
- Filed
- Sep 6, 2023
- Trade date
- Mar 30, 2021
- Filing delay
- 890 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Apr 1, 2021
This filing lists 3 non-derivative transactions. Open-market purchases total $14.0M. It was filed 890 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| William ArsaniCIK 0001848372 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 30, 2021 | Common Stock | CConversionAcquired | +1,217,627 | –F1 | – | 1,217,627 | Indirect | |
| Mar 30, 2021 | Common Stock | CConversionAcquired | +814,874 | –F1 | – | 814,874 | Indirect | |
| Mar 30, 2021 | Common Stock | PPurchaseAcquired | +700,000 | $20.00 | +$14,000,000 | 700,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.
Referenced by the price of 2 transactions in Table I.
- F2
This Form 4 is being amended to correct the amount of securities beneficially owned by the Reporting Person. This error resulted in the misreporting of the amount of securities beneficially owned by the Reporting Person on subsequent reports.
- F3
Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II") and Logos SPV 1 LP ("SPV 1"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. Logos Opportunities II GP LLC ("GP II") is the general partner of SPV 1. The Reporting Person is the Managing Member of both GP I and GP II. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F4
Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.